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Population-adjusted treatment comparisons 
 
Estimates based on Matching-Adjusted Indirect Comparisons (MAIC) and 
Simulated Treatment Comparisons (STC) 
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Aims 
• Review the properties and assumptions of methods for population-adjusted treatment comparison, 
including Matching-Adjusted Indirect Comparison (MAIC) and Simulated Treatment Comparison 
(STC). 
• Provide guidance on their use in health technology appraisal (HTA). 
 
More information is available in NICE DSU Technical Support Document 18 (Phillippo et al. 2016). 
Target population and shared effect modifier assumption 
The results of a population-adjusted analysis are irrelevant if they cannot be obtained for the correct target 
population. The shared effect modifier assumption holds for active treatments B and C if: 
a) B and C have the same effect modifiers, and 
b) The change in treatment effect caused by each effect modifier is the same for B and C 
If this is the case, then the relative effect is valid for any population. The shared effect modifier 
assumption is evaluated on a clinical basis, and is more likely to be satisfied by treatments in the same class. 
BCd
Background 
In HTA submissions, a company wishes to compare their treatment B with that of a competitor, C. Standard 
indirect comparison and network meta-analysis assume that there are no differences in effect modifiers 
between the populations, and require a common comparator or a connected network — neither of which 
may be the case. 
In an ideal scenario, individual patient data (IPD) would be available on all trials, and an IPD Network 
Meta-Regression could be performed. However, it is much more likely that a company only has access to 
IPD on their own trials and published aggregate summaries from their competitor’s. 
Population adjustment methods seek to use available IPD to adjust for any between-trial differences, or 
even reconcile unconnected networks, under certain constancy assumptions (Figure 1). 
Recommendations 
The focus of the following recommendations is statistical and clinical validity, transparency, and consistency in the use of population adjustment methods for health technology appraisal. 
Recommendation 3 Submissions using population-adjusted analyses in an unconnected network need 
to provide evidence that absolute outcomes can be predicted with sufficient accuracy in relation to the 
relative treatment effects, and present an estimate of the likely range of residual systematic error in the 
“adjusted” unanchored comparison. 
Recommendation 1 When connected evidence with a common comparator is available, a population-
adjusted anchored indirect comparison may be considered. Unanchored indirect comparisons may only be 
considered in the absence of a connected network of randomised evidence, or where there are single-arm 
studies involved. 
Recommendation 2 Submissions using population-adjusted analyses in a connected network need to 
provide evidence that they are likely to produce less biased estimates of treatment differences than could 
be achieved through standard methods. 
a) Evidence must be presented that there are grounds for considering one or more variables as effect 
modifiers on the appropriate transformed scale. This can be empirical evidence, or an argument based 
on biological plausibility. 
b) Quantitative evidence must be presented that population adjustment would have a material impact on 
relative effect estimates due to the removal of substantial bias. 
Unanchored comparisons require much stronger assumptions, so anchored comparisons are always 
preferred. 
Justification is required for moving away from standard anchored methods. This is in line with the NICE 
Methods Guide, which states that “treatment effect modifiers should be identified before data analysis, 
either by a thorough review of the subject area or discussion with experts in the clinical discipline.” 
If this evidence cannot be provided, the amount of bias in an unanchored comparison is unknown and likely 
to be substantial.  
Recommendation 4 The following variables should be adjusted for in a population-adjusted analysis: 
a) For an anchored indirect comparison, propensity score weighting methods should adjust for all effect 
modifiers (in imbalance or not), but no prognostic variables. Outcome regression methods should adjust 
for all effect modifiers in imbalance, and any other prognostic variables and effect modifiers that 
improve model fit. 
b) For an unanchored indirect comparison, both propensity score weighting and outcome regression 
methods should adjust for all effect modifiers and prognostic variables, in order to reliably predict 
absolute outcomes. 
Recommendation 5 Indirect comparisons should be carried out on the linear predictor scale, with the 
same link functions that are usually employed for those outcomes. 
Recommendation 6 The target population for any treatment comparison must be explicitly stated, and 
population-adjusted estimates of the relative treatment effects must be generated for this target 
population. 
For anchored comparisons, only adjusting for effect modifiers minimises bias without unnecessarily 
reducing precision. Unanchored comparisons require all covariates to be adjusted for, as predictions of 
absolute outcomes are required. 
In line with general modelling practice (NICE, ISPOR).  Effect modification is defined with respect to this 
scale, so must also be clinically meaningful. 
Population adjustment methods are only useful for decision making if they can produce estimates for the 
appropriate target population; the shared effect modifier assumption may be utilised if appropriate. 
Anchored 
Propensity score reweighting Outcome regression 
1. Provide evidence for effect modifier status on a suitable transformed scale. 
2. Provide evidence that effect modifiers are in substantial imbalance between studies. 
3a. Create a logistic propensity score model, 
which includes all effect modifiers but no 
prognostic variables. This is equivalent to a 
model on the log of the weights: 
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3b. Estimate the weights using the method of 
moments to match effect modifier distributions 
between trials. This is equivalent to minimising 
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4. Predict outcomes on treatments A and B in 
the AC trial by reweighting the outcomes of the 
AB individuals: 
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3. Fit an outcome model in the AB trial, 
which includes all effect modifiers in imbalance 
and any other prognostic variables or effect 
modifiers that improve model fit: 
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4. Predict transformed outcomes on 
treatments A and B in the AC trial using the 
outcome model: 
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5. Form the anchored indirect comparison in the AC population as: 
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6. Calculate standard errors using a robust 
sandwich estimator, bootstrapping, or Bayesian 
techniques. 
7. If justified, use the shared effect modifier assumption to transport the  estimate into the 
target population for the decision. Otherwise, comment on the representativeness of the AC popula-
tion to the true target population. 
( )
ˆ
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6. Calculate standard errors using the 
outcome model. 
8. Present the distribution of estimated 
weights, and effective sample size. 
8. Present standard model fit statistics. 
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Figure I: Forms of indirect comparisons and constancy assumptions 
Propensity score reweighting Outcome regression 
1a. Create a logistic propensity score model, 
which includes all effect modifiers and 
prognostic variables. This is equivalent to a 
model on the log of the weights: 
 
  0 1log
T
i iw   α X
1b. Estimate the weights using the method of 
moments to match effect modifier distributions 
between trials. This is equivalent to minimising 
 
when . 
 ( ) 11 exp
B BN
i
T
i Xα
( )
EM
C X 0
2. Predict outcomes on treatment B in the C 
trial by reweighting the outcomes of the B 
individuals: 
 
( )
( )
( )1
( )
1
ˆ
ˆ
ˆ
B B
B B
N
i B ii
B C N
ii
w
Y
Y
w





1. Fit an outcome model in the A trial, which 
includes all effect modifiers and prognostic 
variables: 
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2. Predict transformed outcomes on 
treatments A and B in the C trial using the 
outcome model: 
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3. Form the unanchored indirect comparison in the C population as: 
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4. Calculate standard errors using a robust 
sandwich estimator, bootstrapping, or Bayesian 
techniques. 
6. If justified, use the shared effect modifier assumption to transport the  estimate into the 
target population for the decision. Otherwise, comment on the representativeness of the C population 
to the true target population. 
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4. Calculate standard errors using the 
outcome model. 
7. Present the distribution of estimated 
weights, and effective sample size. 
5. Provide evidence that absolute outcomes can be predicted with sufficient accuracy in relation to 
the relative treatment effects, and present an estimate of the likely range of residual systematic error. If 
this evidence cannot be provided or is limited, then state that the amount of bias in the indirect 
comparison is likely to be substantial, and could even exceed the magnitude of treatment effects which 
are being estimated. 
7. Present standard model fit statistics. 
Unanchored 
Processes for population-adjusted indirect comparison 
Signorovitch JE, Wu EQ, Yu AP, Gerrits CM, Kantor E, Bao YJ, Gupta SR, Mulani PM. 2010. Comparative 
effectiveness without head-to-head trials a method for matching-adjusted indirect comparisons applied to 
psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 28(10):935-945.  
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If effect modification is present on a given scale, relative effects between 
treatments on that scale are specific to a given population P, where and are the mean 
outcomes on each treatment.  
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In a connected network with AB and AC trials, an anchored comparison can be made using 
randomisation with a common comparator A (Figure 1a). 
In an unconnected network where there is no common comparator or there are single-arm studies, an 
unanchored comparison is the only option (Figure 1b). 
Methods for population adjustment 
Population adjustment methods are broadly of two types: 
• Propensity score reweighting, such as Matching-Adjusted Indirect Comparison (MAIC; Signorovitch et 
al. 2010), where individuals in the AB trial are weighted so that the reweighted covariate distribution 
matches that of the aggregate AC trial. 
• Outcome regression, such as Simulated Treatment Comparison (STC; Caro and Ishak 2010), where a 
model is fitted in the AB trial and used to predict outcomes in the aggregate AC trial. 
